newsfilter
← Latest News
GlobeNewswire·

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced